 Harvard Bioscience is a small-cap life-science technology company that is trading at a significant discount after falling 67 over the past twelve months despite the tickers significant upside potential. I believe the market-wide sell-off has provided me with an opportunity to grow HBIO into a larger element of my Compounding Healthcare Bio Boom Portfolio. 